Takeda Pharmaceutical Company Limited

Takeda San Diego, Inc.

Cardurion Pharmaceuticals, LLC

Takeda California, Inc.

Mark Sabat

Haixia Wang

Stephen L Gwaltney

Zacharia S Cheruvallath

Nicholas Scorah

Mingnam Tang

Joanne Miura

John David Lawson

Phong H Vu

Jun Feng

Christopher Ronald Smith

Lily Kwok

Prasuna Guntupalli

Haxia Wang

Jeffrey Alan Stafford

Junya Shirai

Xiaolun Wang

Tomohiro Okawa

Keiko Kakegawa

Minoru Yoshida

John S Tyhonas

Terufumi Takagi

Andrew John Jennings

Yasufumi Miyamoto

Rei Okamoto

Akito Shibuya

Zenyu Shiokawa

Yoichi Nishikawa

Yuta Tanaka

Yoshito Terao

Nobuyuki Matsunaga

Takafumi Yukawa

Mallareddy Komandla

Takeshi Yoshikawa

Takashi Nakahata

Hiroki Takahagi

Paul Tanis

Toufike Kanouni

Stephen W Kaldor

Young K Chen

Anthony R Gangloff

Steven John Woodhead

Beverly Lynn Wolgast

Walter Keung

Christopher Smith

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.

Pyridinyl and fused pyridinyl triazolone derivatives

The present invention provides compounds of formula 1: which are useful as inhibitors of TBK-1, pharmaceutical compositionst thereof, methods for treatment of conditions associated with TBK1, processes for making the compounds and intermediates thereof.

Heteroarylamide inhibitors of TBK1

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R, R, R, R, and Rare defined in the specification. The compounds are inhibitors of Bruton's tyrosine kinase (BTK). This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with BTK.

Cinnoline derivatives

Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Glucokinase activators

The present invention provides ALK5 inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, methods of making the compounds and intermediates thereof; and methods of using the compounds.

Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5

Pyrazole and fused pyrazole glucokinase activators

Compounds of the following formula are provided for use with glucokinase: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Growing community of inventors

San Diego, CA, United States of America

Mark Sabat